Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows
https://www.henryford.com/news/2020/07/hydro-treatment-study
https://www.ijidonline.com/article/S1201-9712(20)30534-8/pdf
It's positive for HCQ, but observational (not randomized).
As of May27, 2020 there areover 1,678,843confirmed cases of COVID-19 claiming more than 100,000lives in the Unites States. Currently there is no known effective therapy or vaccine.
-According to a protocol-based treatment algorithm, among hospitalized patients, use of hydroxychloroquine alone and in combination withazithromycin was associated with a significant reduction in-hospital mortality compared to not receiving hydroxychloroquine.
-Findings of this observational study providecrucial data on experience with hydroxychloroquine therapy, providing necessary interim guidance for COVID-19 therapeutic practice.
Abstract:Significance:The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies.
Objective:The purpose of this study was to evaluate the role of hydroxychloroquine therapyalone and in combination with azithromycinin hospitalized patientspositive for COVID-19.
Design:Multi-centerretrospective observationalstudy Setting:The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; the largest of hospitals is an 802-bed quaternary academic teaching hospital in urban Detroit, Michigan.
Participants:Consecutive patients hospitalized with a COVID-related admission in the health system from March 10,2020 to May 2,2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48 hours unless expired within 24 hours.
Exposure:Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither.
Main Outcome:The primary outcome was in-hospital mortality.
Results:Of 2,541 patients, with a median total hospitalization time of 6 days(IQR: 4-10 days), median age was64 years (IQR:53-76 years), 51% male, 56% African American, withmedian time to follow-up of28.5 days (IQR:3-53).Overallin-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment:hydroxychloroquine+azithromycin, 157/783 (20.1% [95% CI:17.3%-23.0%]), hydroxychloroquine alone,162/1202 (13.5% [95% CI:11.6%-15.5%]),azithromycin alone, 33/147 (22.4% [95% CI:16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI:22.2%-31.0%]). Primary cause of mortality was respiratory failure(88%); no patient had documented torsades de pointes.From Cox regression modeling, predictors of mortality were age >65 years (HR:2.6[95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD (HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5[95%CI:1.1-2.1]), and ventilator use during admission (HR:2.2[95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, andhydroxychloroquine+azithromycin 71% compared to neither treatment (p<0.001).Conclusions and
Relevance:In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.
Another study that will be ignored by the MSM until after the election.